Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Mar-Apr;22(2):79-84.
doi: 10.1016/j.bjid.2017.10.009. Epub 2018 Feb 17.

Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder

Jose Abraão Carneiro Neto  1 , Silvane Braga Santos  2 , Gloria Orge Orge  3 , Davi Tanajura  4 , Lucia Passos  3 , Cassius José Oliveira  4 , Rosana Andrade  4 , Cláudio Galeno de Melo  5 , Ubirajara Barroso Jr  5 , Edgar M Carvalho  6
Affiliations

Onabotulinumtoxin type A improves lower urinary tract symptoms and quality of life in patients with human T cell lymphotropic virus type 1 associated overactive bladder

Jose Abraão Carneiro Neto et al. Braz J Infect Dis. 2018 Mar-Apr.

Abstract

Aim: To evaluate the efficacy of the onabotulinum toxin type A in the treatment of HTLV-1 associated overactive bladder and its impact on quality of life (QoL).

Methods: Case series with 10 patients with overactive bladder refractory to conservative treatment with anticholinergic or physical therapy. They received 200Ui of onabotulinumtoxin type A intravesically and were evaluated by overactive bladder symptoms score (OABSS) and King's Health Questionnaire.

Results: The mean (SD) of the age was 52+14.5 years and 60% were female. All of them had confirmed detrusor overactivity on urodynamic study. Seven patients had HAM/TSP. The median and range of the OABSS was 13 (12-15) before therapy and decreased to 1.0 (0-12) on day 30 and to 03 (0-14) on day 90 (p<0.0001). There was a significant improvement in 8 of the 9 domains of the King's Health Questionnaire after the intervention. Hematuria, urinary retention and urinary infection were the complications observed in 3 out of 10 patients. The mean time to request retreatment was 465 days.

Conclusion: Onabotulinum toxin type A intravesically reduced the OABSS with last long effect and improved the quality of life of HTLV-1 infected patients with severe overactive bladder.

Keywords: HTLV-1; Onabotulinum toxin; Overactive bladder.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Kaplan–Meier curve. Survival analysis in HTLV-1 infected patients with refractory overactive bladder submitted to intravesical application of onabotulinumtoxin A. Time to request retreatment or to return to previous treatment OABSS.
See this image and copyright information in PMC

References

    1. Gessain A., Cassar O. Epidemiological aspects and world distribution of HTLV-1 infection. Front Microbiol. 2012;3:388. - PMC - PubMed
    1. Souza A., Tanajura D., Toledo-Cornell C., Santos S., Carvalho E.M. Immunopathogenesis and neurological manifestations associated to HTLV-1 infection. Rev Soc Bras Med Trop. 2012;45:545–552. - PubMed
    1. Carod-Artal F.J., Mesquita H.M., Ribeiro Lda S. Neurological symptoms and disability in HTLV-1 associated myelopathy. Neurologia. 2008;23:78–84. - PubMed
    1. Champs A.P., Passos V.M., Barreto S.M., Vaz L.S., Ribas J.G. HTLV-1 associated myelopathy: clinical and epidemiological profile in a 10-year case series study. Rev Soc Bras Med Trop. 2010;43:668–672. - PubMed
    1. Castro N.M., Rodrigues W., Jr., Freitas D.M., Muniz A., Oliveira P., Carvalho E.M. Urinary symptoms associated with human T-cell lymphotropic virus type I infection: evidence of urinary manifestations in large group of HTLV-I carriers. Urology. 2007;69:813–818. - PubMed

Substances